Skip to main content
Erschienen in: Current Gastroenterology Reports 1/2011

01.02.2011

Management of Refractory Ascites and Hepatorenal Syndrome

verfasst von: Amy N. Sussman, Thomas D. Boyer

Erschienen in: Current Gastroenterology Reports | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

One of the most common manifestations of the development of portal hypertension in the patient with cirrhosis is the appearance of ascites. Once ascites develops, the prognosis worsens and the patient becomes susceptible to complications such as bacterial peritonitis, hepatic hydrothorax, hyponatremia, and complications of diuretic therapy. As the liver disease progresses, the ascites becomes more difficult to treat and many patients develop renal failure. Most patients can be managed by diuretics which, when used correctly, will control the ascites. Spontaneous bacterial peritonitis can be treated effectively, but portends a worse prognosis. Once the ascites becomes refractory to diuretics, liver transplantation is the best option, although use of transjugular intrahepatic portosystemic shunts will control the ascites in many patients. Lastly, the development of hepatorenal syndrome indicates the patient’s liver disease is advanced, and transplantation again is the best option. However, use of vasoconstrictors may improve renal function in some patients, helping in their management while they await a liver transplant.
Literatur
1.
Zurück zum Zitat Planas R, Montoliu S, Balleste B, et al.: Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006;4:1385–94.CrossRefPubMed Planas R, Montoliu S, Balleste B, et al.: Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006;4:1385–94.CrossRefPubMed
2.
Zurück zum Zitat Salerno F, Camma C, Enea M, et al.: Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007;133:825–34.CrossRefPubMed Salerno F, Camma C, Enea M, et al.: Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007;133:825–34.CrossRefPubMed
3.
Zurück zum Zitat Gines P, Cardenas A: The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis 2008;28:43–58.CrossRefPubMed Gines P, Cardenas A: The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis 2008;28:43–58.CrossRefPubMed
4.
Zurück zum Zitat Sort P, Navasa M, Arroyo V, et al.: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403–9.CrossRefPubMed Sort P, Navasa M, Arroyo V, et al.: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403–9.CrossRefPubMed
5.
Zurück zum Zitat Bernard B, Grange J-D, Khac EN, et al.: Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding. A meta-analysis. Hepatology 1999;29:1655–61.CrossRefPubMed Bernard B, Grange J-D, Khac EN, et al.: Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding. A meta-analysis. Hepatology 1999;29:1655–61.CrossRefPubMed
6.
Zurück zum Zitat Fernandez J, Navasa M, Planas R, et al.: Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818–24.CrossRefPubMed Fernandez J, Navasa M, Planas R, et al.: Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818–24.CrossRefPubMed
7.
Zurück zum Zitat Angeli P, Wong F, Watson H, et al.: Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006;44:1535–42.CrossRefPubMed Angeli P, Wong F, Watson H, et al.: Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006;44:1535–42.CrossRefPubMed
8.
Zurück zum Zitat Boyer TD: Tolvaptan and hyponatremia. Hepatology 2010;51:699–702.PubMed Boyer TD: Tolvaptan and hyponatremia. Hepatology 2010;51:699–702.PubMed
9.
Zurück zum Zitat Schrier RW, Gross P, Gheorghiade M, et al.: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099–2112.CrossRefPubMed Schrier RW, Gross P, Gheorghiade M, et al.: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099–2112.CrossRefPubMed
10.
Zurück zum Zitat • Kim WR, Biggins SW, Kremers WK, et al.: Hyponatremia and mortality among patients waiting for liver transplantation. N Engl J Med 2008;359:1018–26. This work defined the influences of hyponatremia on survival in patients with advanced liver disease. Hyponatremia is an independent risk factor of death and may be added to the MELD score for determining which patients should receive an organ for liver transplantation. CrossRefPubMed • Kim WR, Biggins SW, Kremers WK, et al.: Hyponatremia and mortality among patients waiting for liver transplantation. N Engl J Med 2008;359:1018–26. This work defined the influences of hyponatremia on survival in patients with advanced liver disease. Hyponatremia is an independent risk factor of death and may be added to the MELD score for determining which patients should receive an organ for liver transplantation. CrossRefPubMed
12.
Zurück zum Zitat Boyer TD, Haskel Z: AASLD Practice Guidelines: The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005;41:386–400.CrossRefPubMed Boyer TD, Haskel Z: AASLD Practice Guidelines: The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005;41:386–400.CrossRefPubMed
13.
Zurück zum Zitat Arroyo V, Gines P, Guevara M, Rodes J: Renal dysfunction in cirrhosis: pathophysiology, clinical features and therapy. In Hepatology: A textbook of liver disease, Ed. 5, Zakim D and Boyer TD eds, WB Saunders, 2006, p. 417–452. Arroyo V, Gines P, Guevara M, Rodes J: Renal dysfunction in cirrhosis: pathophysiology, clinical features and therapy. In Hepatology: A textbook of liver disease, Ed. 5, Zakim D and Boyer TD eds, WB Saunders, 2006, p. 417–452.
14.
Zurück zum Zitat Tito L, Gines P, Arroyo V, et al.: Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology 1990;98:146–51.PubMed Tito L, Gines P, Arroyo V, et al.: Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology 1990;98:146–51.PubMed
15.
Zurück zum Zitat Angermayr B, Cejna M, Koenig F, et al.: Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stent grafts versus bare stents. Hepatology 2003;38:1043–50.PubMed Angermayr B, Cejna M, Koenig F, et al.: Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stent grafts versus bare stents. Hepatology 2003;38:1043–50.PubMed
16.
Zurück zum Zitat Nair S, Verma S, Thuluvath PJ: Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;1179–85. Nair S, Verma S, Thuluvath PJ: Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;1179–85.
17.
Zurück zum Zitat Weismuller TJ, Prokein J, Becker T, et al.: Prediction of survival after liver transplantation by pre-transplant parameters. Scan J Gastroenterol 2008;43:736–746.CrossRef Weismuller TJ, Prokein J, Becker T, et al.: Prediction of survival after liver transplantation by pre-transplant parameters. Scan J Gastroenterol 2008;43:736–746.CrossRef
18.
Zurück zum Zitat Schrier RW, Arroyo V, Bernardi M, et al.: Peripheral arterial vasodilaton hypothesis: a proposal for the initation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151–7.CrossRefPubMed Schrier RW, Arroyo V, Bernardi M, et al.: Peripheral arterial vasodilaton hypothesis: a proposal for the initation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151–7.CrossRefPubMed
19.
Zurück zum Zitat • Ginès P, Schrier RW: Renal failure in cirrhosis. N Engl J Med 2009;361;13: 1279–1290. This excellent review discusses the pathogenesis of renal failure in patients with cirrhosis. Also, current treatments are reviewed and guidelines provided to the clinician on evaluation and management of the patient with cirrhosis and renal failure. CrossRefPubMed • Ginès P, Schrier RW: Renal failure in cirrhosis. N Engl J Med 2009;361;13: 1279–1290. This excellent review discusses the pathogenesis of renal failure in patients with cirrhosis. Also, current treatments are reviewed and guidelines provided to the clinician on evaluation and management of the patient with cirrhosis and renal failure. CrossRefPubMed
20.
Zurück zum Zitat Iwakiri Y: The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol 2007;Suppl 3:S288–S294.CrossRef Iwakiri Y: The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol 2007;Suppl 3:S288–S294.CrossRef
21.
Zurück zum Zitat Martin, PY, Ginès P, Schrier RW: Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339:533–541.CrossRefPubMed Martin, PY, Ginès P, Schrier RW: Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339:533–541.CrossRefPubMed
22.
Zurück zum Zitat Arroyo V, Ginès P, Gerbes AL, et al.: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164–176.CrossRefPubMed Arroyo V, Ginès P, Gerbes AL, et al.: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164–176.CrossRefPubMed
23.
Zurück zum Zitat Wiest R, Das S, Cadelina G, et al.: Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J. Clin Invest 1999;104:1223–1233.CrossRefPubMed Wiest R, Das S, Cadelina G, et al.: Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J. Clin Invest 1999;104:1223–1233.CrossRefPubMed
24.
Zurück zum Zitat Wiest R, Garcia-Tsao G: Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41:422–433.CrossRefPubMed Wiest R, Garcia-Tsao G: Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41:422–433.CrossRefPubMed
25.
Zurück zum Zitat Albillos A, de la Hera A, González M, et al.: Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003;37:208–217.CrossRefPubMed Albillos A, de la Hera A, González M, et al.: Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003;37:208–217.CrossRefPubMed
26.
Zurück zum Zitat Fraces R, Zapater P, Gonzalez M, et al.: Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008;47:978–985.CrossRef Fraces R, Zapater P, Gonzalez M, et al.: Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008;47:978–985.CrossRef
27.
Zurück zum Zitat Bataller R, Ginès P, Guevara M, Arroyo V: Hepatorenal syndrome. Semin Liver Dis 1997;17:233–247.CrossRefPubMed Bataller R, Ginès P, Guevara M, Arroyo V: Hepatorenal syndrome. Semin Liver Dis 1997;17:233–247.CrossRefPubMed
28.
Zurück zum Zitat Wadeo HM, Mai ML, Absan N, Gonwa TA: Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006;1:1066.CrossRef Wadeo HM, Mai ML, Absan N, Gonwa TA: Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006;1:1066.CrossRef
29.
Zurück zum Zitat Salerno F, Gerbes A, Ginès P, et al.: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310–1318.PubMed Salerno F, Gerbes A, Ginès P, et al.: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310–1318.PubMed
30.
Zurück zum Zitat MacAulay J, Thompson K, Kibert BA, et al.: Serum creatinine in patients with advanced liver disease is of limited value for identification of moderate renal dysfunction; are the equations for estimating renal function better? Can J Gastroenterol 2006;20:521–526.PubMed MacAulay J, Thompson K, Kibert BA, et al.: Serum creatinine in patients with advanced liver disease is of limited value for identification of moderate renal dysfunction; are the equations for estimating renal function better? Can J Gastroenterol 2006;20:521–526.PubMed
31.
Zurück zum Zitat Moore KP, Wong F, Ginès P, et al.: The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Heptatology 2003;38:258–266.CrossRef Moore KP, Wong F, Ginès P, et al.: The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Heptatology 2003;38:258–266.CrossRef
32.
Zurück zum Zitat Salerno F, Gerbes A, Gines P, et al.: Diagnosis, prevention, and treatment of the hepatorenal syndrome in cirrhosis: a consensus workshop of the International Ascites Club. Gut 2007;56:1310–1318.PubMed Salerno F, Gerbes A, Gines P, et al.: Diagnosis, prevention, and treatment of the hepatorenal syndrome in cirrhosis: a consensus workshop of the International Ascites Club. Gut 2007;56:1310–1318.PubMed
33.
Zurück zum Zitat • Garcia-Tsao G, Parikh CR, Viola A: Acute kidney injury in cirrhosis. Hepatology 2008;48:2064–2077. The causes of renal failure in patients admitted with cirrhosis are defined. Most patients with cirrhosis and renal failure do not have hepatorenal syndrome, but instead have types of renal failure that are reversible. The clinician needs to be aware of all causes of renal failure in this patient population so that appropriate therapy can be given. CrossRefPubMed • Garcia-Tsao G, Parikh CR, Viola A: Acute kidney injury in cirrhosis. Hepatology 2008;48:2064–2077. The causes of renal failure in patients admitted with cirrhosis are defined. Most patients with cirrhosis and renal failure do not have hepatorenal syndrome, but instead have types of renal failure that are reversible. The clinician needs to be aware of all causes of renal failure in this patient population so that appropriate therapy can be given. CrossRefPubMed
34.
Zurück zum Zitat Angeli P, Merkel C: Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008;48:Suppl 1:S93–S103.CrossRefPubMed Angeli P, Merkel C: Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008;48:Suppl 1:S93–S103.CrossRefPubMed
36.
37.
Zurück zum Zitat Gluud LL, Kjaer MS, Christensen E: Terlipressin for hepatorenal syndrome. Cochrane Database Sys Rev 2006;4:CD005162. Gluud LL, Kjaer MS, Christensen E: Terlipressin for hepatorenal syndrome. Cochrane Database Sys Rev 2006;4:CD005162.
38.
Zurück zum Zitat Martin-Llahi M, Pepin MN, Guevara M, et al.: Terlipressin and albumin vs. Albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352–1359.CrossRefPubMed Martin-Llahi M, Pepin MN, Guevara M, et al.: Terlipressin and albumin vs. Albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352–1359.CrossRefPubMed
39.
Zurück zum Zitat • Sanyal AK, Boyer T, Garcia-Tsao G, et al.: A randomized, prospective, double blind, placebo-controlled study of terlipressin for type I hepatorenal syndrome. Gastroenterology 2008, 134:1360–1368. This is the largest placebo-controlled trial of a vasopressor in the treatment of hepatorenal syndrome type 1. Terlipressin reversed renal failure in more patients as compared to those receiving placebo. The results of this and other trials establish that the hyperdynamic circulation and resulting renal underperfusion are the basis for the development of the hepatorenal syndrome. CrossRefPubMed • Sanyal AK, Boyer T, Garcia-Tsao G, et al.: A randomized, prospective, double blind, placebo-controlled study of terlipressin for type I hepatorenal syndrome. Gastroenterology 2008, 134:1360–1368. This is the largest placebo-controlled trial of a vasopressor in the treatment of hepatorenal syndrome type 1. Terlipressin reversed renal failure in more patients as compared to those receiving placebo. The results of this and other trials establish that the hyperdynamic circulation and resulting renal underperfusion are the basis for the development of the hepatorenal syndrome. CrossRefPubMed
40.
Zurück zum Zitat Duvoux C, Zanditenas D, Hézode C, et al.: Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome.: a pilot study. Hepatology 2002;36:374–380.CrossRefPubMed Duvoux C, Zanditenas D, Hézode C, et al.: Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome.: a pilot study. Hepatology 2002;36:374–380.CrossRefPubMed
41.
Zurück zum Zitat Angeli P, Volpin R, Gerunda G, et al.: Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999:29:1690–1697.CrossRefPubMed Angeli P, Volpin R, Gerunda G, et al.: Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999:29:1690–1697.CrossRefPubMed
42.
Zurück zum Zitat Esrailian E, Pantangco ER, Kyulo NL, et al.: Octreotide/midodrine therapy significnatly improves renal function and 30-day survival in patients with type I hepatorenal syndrome. Dig Dis Sci 2007;52:742–748.CrossRefPubMed Esrailian E, Pantangco ER, Kyulo NL, et al.: Octreotide/midodrine therapy significnatly improves renal function and 30-day survival in patients with type I hepatorenal syndrome. Dig Dis Sci 2007;52:742–748.CrossRefPubMed
43.
Zurück zum Zitat Pomier-Layrargues G, Paquin SC, Hassoun Z, et al.: Octreotide in hepatorenal syndrome: a randomized, double-bline, placebo-controlled, crossover study. Hepatology 2003;1:238–243.CrossRef Pomier-Layrargues G, Paquin SC, Hassoun Z, et al.: Octreotide in hepatorenal syndrome: a randomized, double-bline, placebo-controlled, crossover study. Hepatology 2003;1:238–243.CrossRef
44.
Zurück zum Zitat Alessandria C, Ozdogan O, Guevara M, et al.: MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005;41:1282–1289.CrossRefPubMed Alessandria C, Ozdogan O, Guevara M, et al.: MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005;41:1282–1289.CrossRefPubMed
45.
Zurück zum Zitat Gonwa TA, Klintmalm GB, Levy M, et al.: Impact of pretransplant renal function on survival after liver transplantation. Transplantation. 1995;59:361–365.PubMed Gonwa TA, Klintmalm GB, Levy M, et al.: Impact of pretransplant renal function on survival after liver transplantation. Transplantation. 1995;59:361–365.PubMed
46.
Zurück zum Zitat Restuccia T, Ortega R, Guevara M, et al.: Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. J Hepatol 2004;40:140–146.CrossRefPubMed Restuccia T, Ortega R, Guevara M, et al.: Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. J Hepatol 2004;40:140–146.CrossRefPubMed
47.
Zurück zum Zitat Wong LP, Blackley MP, Andreoni KA, et al.: Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int 2005;1:362–370.CrossRef Wong LP, Blackley MP, Andreoni KA, et al.: Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int 2005;1:362–370.CrossRef
48.
Zurück zum Zitat Wong F, Sniderman K, Liu P, Blendis L: The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. Gastroenterology 1997; 3:899–907.CrossRef Wong F, Sniderman K, Liu P, Blendis L: The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. Gastroenterology 1997; 3:899–907.CrossRef
49.
Zurück zum Zitat Guevara M, Ginès P, Bandi JC, et al.: Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416–422.CrossRefPubMed Guevara M, Ginès P, Bandi JC, et al.: Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416–422.CrossRefPubMed
50.
Zurück zum Zitat Brensing KA, Textor J, Perz J, et al.: Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288–295.CrossRefPubMed Brensing KA, Textor J, Perz J, et al.: Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288–295.CrossRefPubMed
51.
Zurück zum Zitat Wong F, Pantea L, Sniderman K: Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type I hepatorenal syndrome. Hepatology 2004;40:55–64.CrossRefPubMed Wong F, Pantea L, Sniderman K: Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type I hepatorenal syndrome. Hepatology 2004;40:55–64.CrossRefPubMed
52.
Zurück zum Zitat Rasaratnam B, Kaye D, Jennings G, et al.: The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis: a randomized trial. Ann Intern Med 2003;139:186–193.PubMed Rasaratnam B, Kaye D, Jennings G, et al.: The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis: a randomized trial. Ann Intern Med 2003;139:186–193.PubMed
Metadaten
Titel
Management of Refractory Ascites and Hepatorenal Syndrome
verfasst von
Amy N. Sussman
Thomas D. Boyer
Publikationsdatum
01.02.2011
Verlag
Current Science Inc.
Erschienen in
Current Gastroenterology Reports / Ausgabe 1/2011
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-010-0156-6

Weitere Artikel der Ausgabe 1/2011

Current Gastroenterology Reports 1/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.